Compare Quest Diagnostics Inc (DGX) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Duke Energy Corp — how do they compare? Quest Diagnostics Inc trades at $230.31 (market cap $25.48B), while Duke Energy Corp trades at $116.44 (market cap $91.10B). The key difference: Duke Energy Corp is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Duke Energy Corp for 74 Days on average.
| DGX | DUK | |
|---|---|---|
Market Cap | $25.48B | $91.10B |
Volume | 941,866 | 4,199,050 |
Sector | Health | Utilities |
52-Week High | $247.45 | $133.46 |
52-Week Low | $173.49 | $113.23 |
Typical Hold Time | 56 Days | 74 Days |
Enterprise Value | $31.23B | $183.61B |
Dividend Yield | 1.49% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.
DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
